MX2013015419A - Dha y epa en la reduccion de estres oxidante. - Google Patents
Dha y epa en la reduccion de estres oxidante.Info
- Publication number
- MX2013015419A MX2013015419A MX2013015419A MX2013015419A MX2013015419A MX 2013015419 A MX2013015419 A MX 2013015419A MX 2013015419 A MX2013015419 A MX 2013015419A MX 2013015419 A MX2013015419 A MX 2013015419A MX 2013015419 A MX2013015419 A MX 2013015419A
- Authority
- MX
- Mexico
- Prior art keywords
- oxidative stress
- dha
- epa
- reduction
- prevention
- Prior art date
Links
- 230000036542 oxidative stress Effects 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención se refiere generalmente a la prevención o tratamiento de trastornos relacionados con estrés oxidante. Por ejemplo, la presente invención proporciona una composición para usarse en la prevención o tratamiento de trastornos relacionados con estrés oxidante bajo condiciones postoperatorias. Una modalidad de la presente invención es una composición que comprende DHA y EPA como ingredientes activos para usarse en el tratamiento o prevención de estrés oxidante y/o trastornos relacionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11171681A EP2540292A1 (en) | 2011-06-28 | 2011-06-28 | DHA and EPA in the reduction of oxidative stress |
PCT/EP2012/062326 WO2013000895A1 (en) | 2011-06-28 | 2012-06-26 | Dha and epa in the reduction of oxidative stress |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013015419A true MX2013015419A (es) | 2014-03-21 |
Family
ID=44501782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013015419A MX2013015419A (es) | 2011-06-28 | 2012-06-26 | Dha y epa en la reduccion de estres oxidante. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140186454A1 (es) |
EP (3) | EP2540292A1 (es) |
JP (1) | JP6378629B2 (es) |
CN (1) | CN103648494A (es) |
AU (1) | AU2012277977A1 (es) |
BR (1) | BR112013033438A2 (es) |
CA (1) | CA2838976C (es) |
MX (1) | MX2013015419A (es) |
WO (1) | WO2013000895A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105533505B (zh) * | 2016-02-25 | 2017-02-22 | 山东禹王制药有限公司 | 一种咀嚼型鱼油复合软胶囊及其制备方法 |
CN108042522A (zh) * | 2017-12-29 | 2018-05-18 | 广东海洋大学 | 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用 |
CN108354919A (zh) * | 2017-12-29 | 2018-08-03 | 广东海洋大学 | 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用 |
CN109463512A (zh) * | 2018-12-10 | 2019-03-15 | 瞿瀚鹏 | Dha油脂组合物在凝胶糖果中的应用以及凝胶糖果及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
KR20060061409A (ko) * | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
GB0111282D0 (en) * | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
JPWO2003018058A1 (ja) * | 2001-08-22 | 2004-12-09 | 横田 充弘 | 心筋細胞のアポトーシス抑制剤 |
US8729124B2 (en) * | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
CA2397684A1 (en) * | 2002-08-12 | 2004-02-12 | Michael P. Murphy | Mitochondrially targeted antioxidants |
US20060009486A1 (en) * | 2004-07-07 | 2006-01-12 | Gm Pharmaceuticals Inc. | Composition and method for treatment and prevention of coronary artery disease |
JP2008506774A (ja) * | 2004-07-19 | 2008-03-06 | ティア メディカ アクスイェ セルスカプ | タンパク質材料と非酸化性脂肪酸体を含む組成物 |
CA2605928A1 (en) * | 2005-04-21 | 2006-11-02 | Glenn A. Goldstein | N-acetylcysteine amide (nac amide) for treatment of oxidative stress associated with infertility |
US20070020340A1 (en) * | 2005-07-25 | 2007-01-25 | David Rubin | Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension |
ES2393212T3 (es) * | 2006-04-12 | 2012-12-19 | Unilever N.V. | Composición oral con un efecto antienvejecimiento sobre la piel |
US20080015218A1 (en) * | 2006-07-12 | 2008-01-17 | Novus International Inc. | Antioxidant combinations for use in ruminant feed rations having a fat source |
US8410181B2 (en) * | 2006-09-19 | 2013-04-02 | The Trustees Of Columbia University In The City Of New York | Omega-3 diglyceride emulsions |
JP5128828B2 (ja) * | 2007-02-16 | 2013-01-23 | 月桂冠株式会社 | 抗炎症剤及び抗酸化剤 |
US20100056484A1 (en) * | 2008-08-26 | 2010-03-04 | Scott Farese | Dietary supplemental composition effective for enhancing cognitive performance, elevating mood and reducing oxidative stress |
WO2010074940A1 (en) * | 2008-12-23 | 2010-07-01 | Alcon Research, Ltd. | Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response |
US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
US8426368B2 (en) * | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
EP2425833A1 (de) * | 2010-09-03 | 2012-03-07 | Fresenius Kabi Deutschland GmbH | Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie |
-
2011
- 2011-06-28 EP EP11171681A patent/EP2540292A1/en not_active Withdrawn
-
2012
- 2012-06-26 CN CN201280031582.9A patent/CN103648494A/zh active Pending
- 2012-06-26 CA CA2838976A patent/CA2838976C/en active Active
- 2012-06-26 MX MX2013015419A patent/MX2013015419A/es not_active Application Discontinuation
- 2012-06-26 EP EP12730510.0A patent/EP2726070A1/en not_active Withdrawn
- 2012-06-26 AU AU2012277977A patent/AU2012277977A1/en not_active Abandoned
- 2012-06-26 US US14/127,606 patent/US20140186454A1/en not_active Abandoned
- 2012-06-26 EP EP20140180286 patent/EP2801356A3/en not_active Withdrawn
- 2012-06-26 JP JP2014517649A patent/JP6378629B2/ja active Active
- 2012-06-26 BR BR112013033438A patent/BR112013033438A2/pt not_active IP Right Cessation
- 2012-06-26 WO PCT/EP2012/062326 patent/WO2013000895A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20140186454A1 (en) | 2014-07-03 |
EP2801356A2 (en) | 2014-11-12 |
AU2012277977A1 (en) | 2014-01-09 |
WO2013000895A1 (en) | 2013-01-03 |
WO2013000895A9 (en) | 2013-02-21 |
JP2014527029A (ja) | 2014-10-09 |
CA2838976C (en) | 2020-01-07 |
EP2726070A1 (en) | 2014-05-07 |
BR112013033438A2 (pt) | 2017-01-31 |
CN103648494A (zh) | 2014-03-19 |
CA2838976A1 (en) | 2013-01-03 |
EP2540292A1 (en) | 2013-01-02 |
EP2801356A3 (en) | 2015-04-29 |
JP6378629B2 (ja) | 2018-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
TN2012000549A1 (en) | Substituted 5-fluoro-1h-pyrazolopyridines and use thereof | |
MY173994A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
IN2012DN00624A (es) | ||
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
MX362185B (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
MX2014005440A (es) | Inhibidores de nicotinamida adenina dinucleotido difosfato oxidasa-4 y uso de los mismos. | |
PH12014501032A1 (en) | 2-thiopyrimidinones | |
NZ702930A (en) | Racecadotril liquid compositions | |
WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
TN2013000239A1 (en) | New form of administration of enkephalinase inhibitor | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
MX2012000006A (es) | L-serina para usarse como un farmaco para prevenir y/o tratar una respuesta inflamatoria de la piel. | |
TN2015000255A1 (fr) | Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses | |
EP2576536A4 (en) | INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE | |
MX2013015419A (es) | Dha y epa en la reduccion de estres oxidante. | |
MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
MX2013002261A (es) | N-fenetiltriazolonacetamidas sustituidas y su uso. | |
IN2015KN00370A (es) | ||
MX2014011218A (es) | Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales. | |
MX337139B (es) | Composicion de miel con l-alanil-l-glutamina. | |
GB201312583D0 (en) | Combination and composition for treating obesity | |
WO2012099420A3 (ko) | 목향 추출물을 포함하는 뇌암 치료용 조성물 및 건강 기능성 식품 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |